Page 83 - AN-3-3

Advanced Neurology mTOR inhibition in epilepsy

streptomycete and isolation of the active principle. J Antibiot 67. Krueger DA, Wilfong AA, Holland-Bouley K, et al.
(Tokyo). 1975;28(10):721-726. Everolimus treatment of refractory epilepsy in tuberous
sclerosis complex. Ann Neurol. 2013;74(5):679-687.
doi: 10.7164/antibiotics.28.721
doi: 10.1002/ana.23960
57. Oshiro N, Yoshino K, Hidayat S, et al. Dissociation of raptor
from mTOR is a mechanism of rapamycin-induced inhibition 68. Franz DN, Belousova E, Sparagana S, et al. Everolimus
of mTOR function. Genes Cells. 2004;9(4):359-366. for subependymal giant cell astrocytoma in patients
with tuberous sclerosis complex: 2-year open-label
doi: 10.1111/j.1356-9597.2004.00727.x
extension of the randomised EXIST-1 study. Lancet Oncol.
58. Zhou H, Luo Y, Huang S. Updates of mTOR inhibitors. 2014;15(13):1513-1520.
Anticancer Agents Med Chem. 2010;10(7):571-581.
doi: 10.1016/S1470-2045(14)70489-9
doi: 10.2174/187152010793498663
69. French JA, Lawson JA, Yapici Z, et al. Adjunctive everolimus
59. Mao B, Zhang Q, Ma L, Zhao DS, Zhao P, Yan P. Overview of therapy for treatment-resistant focal-onset seizures
research into mTOR inhibitors. Molecules. 2022;27(16):5295. associated with tuberous sclerosis (EXIST-3): A phase 3,
doi: 10.3390/molecules27165295 randomised, double-blind, placebo-controlled study. Lancet.
2016;388(10056):2153-2163.
60. Toschi A, Lee E, Xu L, Garcia A, Gadir N, Foster DA.
Regulation of mTORC1 and mTORC2 complex assembly by doi: 10.1016/S0140-6736(16)31419-2
phosphatidic acid: Competition with rapamycin. Mol Cell 70. Franz DN, Lawson JA, Yapici Z, et al. Adjunctive everolimus
Biol. 2009;29(6):1411-1420. therapy for tuberous sclerosis complex-associated refractory
doi: 10.1128/MCB.00782-08 seizures: Results from the postextension phase of EXIST-3.
Epilepsia. 2021;62(12):3029-3041.
61. Foster DA, Toschi A. Targeting mTOR with rapamycin: One
dose does not fit all. Cell Cycle. 2009;8(7):1026-1029. doi: 10.1111/epi.17099
doi: 10.4161/cc.8.7.8044 71. Curatolo P, Franz DN, Lawson JA, et al. Adjunctive
everolimus for children and adolescents with treatment-
62. Franz DN, Leonard J, Tudor C, et al. Rapamycin causes refractory seizures associated with tuberous sclerosis
regression of astrocytomas in tuberous sclerosis complex. complex: Post-hoc analysis of the phase 3 EXIST-3 trial.
Ann Neurol. 2006;59(3):490-498. Lancet Child Adolesc Health. 2018;2(7):495-504.
doi: 10.1002/ana.20784
doi: 10.1016/S2352-4642(18)30099-3
63. Cardamone M, Flanagan D, Mowat D, Kennedy SE, 72. Taboada RG, Riechelmann RP, Mauro C, et al. Everolimus-
Chopra M, Lawson JA. Mammalian target of rapamycin induced pneumonitis in patients with neuroendocrine
inhibitors for intractable epilepsy and subependymal giant neoplasms: Real-world study on risk factors and outcomes.
cell astrocytomas in tuberous sclerosis complex. J Pediatr. Oncologist. 2022;27(2):97-103.
2014;164(5):1195-1200.
doi: 10.1093/oncolo/oyab024
doi: 10.1016/j.jpeds.2013.12.053
73. Franz DN, Krueger DA. mTOR inhibitor therapy as a disease
64. Franz DN, Lawson JA, Yapici Z, et al. Everolimus modifying therapy for tuberous sclerosis complex. Am J Med
for treatment-refractory seizures in TSC: Extension Genet C Semin Med Genet. 2018;178(3):365-373.
of a randomized controlled trial. Neurol Clin Pract.
2018;8(5):412-420. doi: 10.1002/ajmg.c.31655
doi: 10.1212/CPJ.0000000000000514 74. Baas MC, Gerdes VE, Ten Berge IJ, et al. Treatment with
everolimus is associated with a procoagulant state. Thromb
65. Krueger DA, Care MM, Holland K, et al. Everolimus for Res. 2013;132(2):307-311.
subependymal giant-cell astrocytomas in tuberous sclerosis.
N Engl J Med. 2010;363(19):1801-1811. doi: 10.1016/j.thromres.2013.07.004
doi: 10.1056/NEJMoa1001671 75. Duerr M, Glander P, Diekmann F, Dragun D, Neumayer HH,
Budde K. Increased incidence of angioedema with ACE
66. Franz DN, Belousova E, Sparagana S, et al. Efficacy inhibitors in combination with mTOR inhibitors in kidney
and safety of everolimus for subependymal giant cell
astrocytomas associated with tuberous sclerosis complex transplant recipients. Clin J Am Soc Nephrol. 2010;5(4):703-708.
(EXIST-1): A multicentre, randomised, placebo-controlled doi: 10.2215/CJN.07371009
phase 3 trial [published correction appears in Lancet. 76. Chandra A, Rao NS, Malhotra KP, Rastogi M, Khurana R.
2013;381(9861):116]. Lancet. 2013;381(9861):125-132. Everolimus-associated acute kidney injury in patients with
doi: 10.1016/S0140-6736(12)61134-9 metastatic breast cancer. Indian J Nephrol. 2017;27(5):406-409.

Volume 3 Issue 3 (2024) 19 doi: 10.36922/an.3568